BASF touts strong earnings potential of plant-biotech business

08/3/2010 | Wall Street Journal, The

BASF is optimistic that its plant-biotechnology business will generate a considerable amount of money "in the middle of the current decade," a company official said. Stefan Marcinowski, a BASF board member, said the chemicals group's alliance with Monsanto on bioengineered maize and other crops could bring in more than $2 billion in gross sales by 2020.

View Full Article in:

Wall Street Journal, The

Published in Brief: